Edwards Lifesciences (NYSE:EW) Updates FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 2.950-3.050 for the period, compared to the consensus estimate of 3.010. The company issued revenue guidance of $6.6 billion-$6.9 billion, compared to the consensus revenue estimate of $6.7 billion. Edwards Lifesciences also updated its Q3 2026 guidance to 0.710-0.770 EPS.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. BTIG Research lifted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Evercore reiterated an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Barclays reissued an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $99.04.

Edwards Lifesciences Trading Up 4.7%

EW opened at $87.75 on Friday. The stock has a 50-day moving average of $87.70 and a 200 day moving average of $83.89. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29. The firm has a market cap of $50.52 billion, a P/E ratio of 46.82, a P/E/G ratio of 2.12 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts forecast that Edwards Lifesciences will post 3 EPS for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,577 shares of company stock valued at $3,855,527 in the last ninety days. 0.31% of the stock is owned by company insiders.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Leerink Partners upgraded Edwards Lifesciences (EW) from market perform to outperform and set a $101 price target, implying meaningful upside from recent levels. Leerink Partners upgrade
• Positive Sentiment: The company reported strong Q2 results, with revenue up 13.6% year over year to $1.74 billion and adjusted EPS of $0.78, both ahead of Wall Street estimates. Q2 results press release
• Positive Sentiment: Management raised its full-year sales outlook to $6.6 billion-$6.9 billion and increased the low end of guidance, signaling confidence in continued demand for its heart-valve and transcatheter therapies. WSJ guidance update
• Positive Sentiment: Investors also responded favorably to strong sales momentum in the core TAVR franchise and improving expectations for TMTT, which helped push the stock up in extended trading after the earnings release. Reuters earnings article
• Neutral Sentiment: Analysts’ recent coverage remains constructive overall, with multiple firms maintaining or issuing positive targets around the $100-$110 range, reinforcing a favorable sentiment backdrop for the stock. Analyst targets overview

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. Rakuten Securities Inc. lifted its holdings in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the period. Kelleher Financial Advisors bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth $50,000. Finally, Chapman Financial Group LLC purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $63,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.